New hope for Hard-to-Treat HER2 cancers: first human trial begins
NCT ID NCT05523947
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 31 times
Summary
This early-stage study is testing a new drug called YH32367 in people with advanced HER2-positive solid tumors that have spread. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors. About 147 participants will take part in this first-in-human trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 POSITIVE SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ajou University Hospital
RECRUITINGSuwon, Gyeonggi-do, 16499, South Korea
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
-
Austin Health
RECRUITINGMelbourne, Australia
-
Blacktown Hospital
RECRUITINGSydney, Australia
-
Breast Cancer Research Centre - WA
WITHDRAWNPerth, Australia
-
CHA Bundang Medical Center
RECRUITINGSeongnam-si, Gyeonggi-do, 13496, South Korea
-
Catholic University of Korea St. Vincent's Hospital
RECRUITINGSuwon, Gyeonggi-do, 16247, South Korea
-
Chungbuk National University Hospital
RECRUITINGCheongju-si, North Chungcheong, 28644, South Korea
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Gachon Gil University Medical Center
RECRUITINGIncheon, 21565, South Korea
-
Gyeongsang National University Hospital
RECRUITINGJinju, Gyeongsangnam-do, 52727, South Korea
-
Korea University Anam Hospital
RECRUITINGSeoul, 02841, South Korea
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System
RECRUITINGSeoul, 03722, South Korea
-
Southern Oncology Clinical Research Unit
RECRUITINGAdelaide, Australia
-
The Catholic University of Korea, St. Mary's hospital
RECRUITINGSeoul, 06591, South Korea
-
Ulsan University Hospital
RECRUITINGUlsan, 44437, South Korea
-
Vanderbilt Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.